Form PTO	-1449	U.S. Department of Commerce Patent and Trademark Office			ATTY, DOCKET NO. P51355	ERNATIONAL AP 1/519,033	ATIONAL APPLICATION NO. 9,033		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT:					APPLICANT Douglas Nesta				
AUG 2 6 2005					PRIORITY FILING DATE 2 July 2002 GROUP /644			,	
		EST.	U.S. PATE	NT DC	CUMENTS				
Examiner Initial		Document Number	Date	Name		Clas	s Subclass	s Filing Date If Appropriate	
/MD/	AA	6,171,586	9 Jan. 2001	Lam,	, et al.				-
	1		FOREIGN PA	ATENT	DOCUMENTS	1		<u></u>	
		Document Number	Date		Country	Clas	s Subclass	<u>Translation</u> Yes No	
/MD/	BA	WO97/04801	13 Feb. 1997	РСТ	,				
								•	
		OTHER DOCU	MENTS (Including	Autho	r, Title, Date, Pertinent Pa	roes Etc	.)		<u> </u>
	CA				, SmithKline Beecham	<u> </u>	<u> </u>	ND," R	& <i>D</i>
	CD	Focus Drug News (October 4, 1999) World Publications Ltd., ISSN: 1350-1135							
/MD/	/MD/ CB Smith, S., "Technology Evaluation: C242-DM1, ImmunoGen Inc.," Current Opinion in Molecular Therapeutics(2001) 3(2):198-203 (XP-008011026.)								
									
EXAMINER /Marianne Dibrino/				DATE CONSIDERED 05/03/2007					
					lon is in conformance wit copyof this form with nex				

Sheet <u>1</u> of <u>1</u>.

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office			ATTY. DOCKET NO. P51355					
INFORMATION DISCLOSURE STATEMENT					APPLICANT 19791903					
BY APPLICANT					Douglas P. NESTA					
(Use several sheets if necessary)					FIUNG DATE Herewith	GROUP 1644				
			U	.S. PATENT	DOCUMENTS					
Examiner		Document	Date		Name	Class	Subclass	Filing Date		
Initial		Number	ļ					If Appr	opriate	
· · · · · · · · · · · · · · · · · · ·	AA									
			ļ <u>.</u>							
			<u> </u>							
ļ	ļ									
	<u> </u>									
	<u> </u>									
	<u> </u>		<u></u>	<u> </u>	· · · · · · · · · · · · · · · · · · ·					
			FOR	EIGN PATEN	NT DOCUMENTS					
		Document Date			Country Class		Subclass <u>Translation</u>		ation	
	 	Number					<u> </u>	Yes	No	
	-			ļ						
	ļ									
	ļ ·		<u> </u>							
	↓		ļ		·					
		<u> </u>	<u> </u>							
	Ţ <u>.</u>	OTHER DOC	CUMENTS (In	cluding Auti	hor, Title, Date, Pertine	nt Pages, E	tc.)			
/MD/	CA	"Cantuzumab Mertansine ImmunoGen, SmithKline Beecham US FDA accepts IND," R&D Focus Drug News (October 4, 1999) World Publications Ltd., ISSN: 1350-1135								
				··· <u>·</u>	· · · · · · · · · · · · · · · · · ·			 -		
								,		
EXAMINER		/Marianne Dibrino/			DATE CONSIDERED					
					05/03/2007					
EXAMINE	R: Initio	al if citation conside	red, whether	or not citati	ion is in conformance	with MPEP	509; Draw line	through	$\overline{}$	
					copyof this form with n					